Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Safilens is an Italian medical device company that specializes in the design and manufacture of innovative contact lenses. Founded in 2001, the company is recognized for its proprietary Fusiontechnology, which incorporates natural polymers like hyaluronic acid and tamarind seed polysaccharide into the lens matrix. This technology is designed to improve wearer comfort and maintain ocular surface health by providing a continuous release of beneficial substances. Safilens offers a comprehensive portfolio of daily and monthly disposable lenses, including specialized solutions for presbyopia, astigmatism, and myopia management. In 2019, the company was acquired by Bruno Farmaceutici, a move that integrated its contact lens expertise with broader pharmaceutical capabilities. Their products are distributed globally and are characterized by advanced material science and unique manufacturing processes like the Sonic Wave system.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Safilens.